Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice

Human Gene Therapy

Volumn 10, Issue 18, 1999, Pages 3045-3053

  Li, Hong ^a,b   Griscelli, Frank ^a   Lindenmeyer, Frédérique ^c   Opolon, Paule ^a   Sun, Lin Qian ^c   Connault, Elisabeth ^a   Soria, Jeannette ^d   Soria, Claudine ^b,c   Perricaudet, Michel ^a   Yeh, Patrice ^a   Lu, He ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; LIVER BLOOD FLOW; LIVER METASTASIS; MOUSE; NONHUMAN;

ADENOVIRIDAE; ANIMALS; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0033544886     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016438     Document Type: Article

References (29)

1. BOEHM, T., FOLKMAN, J., BROWDER, T., and O'REILLY, M.S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (London) 390, 404-407.
2. CARMELIET, P., STASSEN, J.M., VLAENDEREN, I.V., MEIDELL, R.S., COLLEN, D., and GERARD, R.D. (1997). Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 90, 1527-1534.
3. DEDIEU, J.F., VIGNE, E., TORRENT, C., JULLIEN, C., MAHFOUZ, I., CAILLAUD, J.M., AUBAILLY, N., ORSINI, C., GUILLAUME, J.M., OPOLON, P., DELAERE, P., PERRICAUDET, M., and YEH, P. (1997). Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71, 4626-4637.
4. ELLIS, V., BEHRENDT, N., and DANO, K. (1991). Plasminogen activation by receptor-bound urokinase, a kinetic study with cell-associated and isolated receptor. J. Biol. Chem. 266, 12752-12758.
5. FIDLER, I.J., and ELLIS, L.M. (1994). The implication of angiogenesis to the biology and therapy of cancer metastasis. Cell 79, 185-188.
6. FOLKMAN, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1, 27-31.
7. FOLKMAN, J. (1998). Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. U.S.A. 95, 9064-9066.
8. GRISCELLI, F., LI, H., BENNACEUR-GRISCELLI, A., SORIA, J., OPOLON, P., SORIA, C., PERRICAUDET, M., YEH, P., and LU, H. (1998). Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. U.S.A. 95, 6367-6372.
9. HANAHAN, D., and FOLKMAN, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
10. HERZ, J., and GERARD, R.D. (1993). Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. U.S.A. 90, 2812-2816.
11. HOLMGREN, L., O'REILLY, M.S., and FOLKMAN, J. (1995). Dormancy of micrometastasis: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149-153.
12. KASS-EISLER, A., FALCK-PETERSEN, E., ELFENBEIN, D.H., ALVIRA, M., BUTTRICK, P.M., and LEINWAND, L.A. (1994). The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1, 395-402.
13. LI, H., LU, H., GRISCELLI, F., OPOLON, P., SUN, L.Q., RAGOT, T., LEGRAND, Y., BELIN, D., SORIA, J., SORIA, C., PERRICAUDET, M., and YEH, P. (1998). Adenovirus-mediated delivery of a cell invasion inhibitor suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 5, 1105-1113.
14. LIN, P., BUXTON, J.A., ACHESON, A., RADZIEJEWSKI, C., MAISONPIERRE, P.C., YANCOPOULOS, G.D., CHANNON, K.M., HALE, L.P., DEWHIRST, M.W., GEORGE, S.E., and PETERS, K.G. (1998). Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. U.S.A. 95, 8829-8834.
15. LU, H., YEH, P., GUITTON, J.D., MABILAT, C., DESANLIS, F., MAURY, I., LEGRAND, Y., SORIA, J., and SORIA, C. (1994). Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett. 356, 56-69.
16. LU, H., MABILAT, C., YEH, P., GUITTON, J.D., LI, H., POUCHELET, M., SHOEVAERT, D., LEGRAND, Y., SORIA, J. and SORIA, C. (1996). Blockage of urokinase receptor reduces in vitro the motility and deformability of endothelial cells. FEBS Lett. 380, 21-24.
17. MIN, H.Y., DOYLE, L.V., VITT, C.R., ZANDONELLA, C.L., STRATTON-THOMAS, J.R., SHUMAN, M.A., and ROSENBERG, S. (1996). Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenic mice. Cancer Res. 56, 2428-2433.
18. O'REILLY, M.S., HOLMGREN, L., SHING, Y., CHEN, C., ROSENTHAL, R.A., MOSES, M., LANE, W.S., CAO, Y., SAGE, E.H., and FOLKMAN, J. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
19. QUAX, P.H.A., GRIMBERGEN, J.M., LANSINK, M., BARKER, A.H.F., BLATTER, M.C., BELIN, D., VAN HINSBERGH, V.W.M., and VERHEIJEN, J.H. (1998). Binding of human urokinase-type plasminogen activator to its receptor: Residues involved in species specificity and binding. Arterioscler. Thromb. Vasc. Biol. 18, 693-701.
20. ROTH, J.A., and CRISTIANO, R.J. (1997). Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 89, 21-39.
21. SATO, T.N. (1998). A new approach to fighting cancer? Proc. Natl. Acad. Sci. U.S.A. 95, 5843-5844.
22. STRATFORD-PERRICAUDET, L.D., MAKEH, I., PERRICAUDET, M., and BRIAND, P. (1992). Widespread long-term gene transfer to mouse skeletal muscles and heart via an adenovirus vector. J. Clin. Invest. 90, 626-630.
23. TANAKA, T., KONNO, H., MATSUDA, I., NAKAMURA, S., and BABA, S. (1995). Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res. 55, 836-839.
24. TANAKA, T., MANOME, Y., WEN, P., KUFE, D.W., and FINE, H.A. (1997). Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med. 3, 437-442.
25. TANIGUCHI, T., RIGG, A., and LEMOINE, N.R. (1998). Targeting angiogenesis: Genetic intervention which strikes at the weak link of tumorigenesis. Gene Ther. 5, 1011-1013.
26. VOGEL, C.A., GALMICHE, M.C., and BUCHEGGER, F. (1997). Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 57, 447-453.
27. VUKANOVIC, J., and ISAACS, J.T. (1995). Human prostatic cancer cell are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res. 55, 3517-3520.
28. WEIDNER, N., FOLKMAN, J., POZZA, F., BEVILACQUA, P., ALLHED, E.N., MOORE, D.H., MELI, S., and GASPARINI G. (1992). Tumor angiogenesis: A new significant and independent prognosis indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84, 1875-1887.
29. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GÖNCZÖL, E., and WILSON J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.